Évaluation de l’efficacité du Nutrilarm®, complément nutritionnel à base d’acides gras essentiels polyinsaturés oméga 3 et oméga 6, versus placebo chez des patients atteints de sécheresse oculaire bilatérale modérée et traitée

Creuzot‐Garcher, Catherine; Baudouin, Christophe; Labétoulle, Marc; Pisella, Pierre‐Jean; Mouriaux, Frédéric; Meddeb-Ouertani, Amel; Matri, L. El; Khairallah, Moncef; Brignole-Baudouin, Françoise

doi:10.1016/j.jfo.2011.01.018

Cited by 19 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the exclusion of 294 duplicate articles, 552 articles were assessed for eligibility. Finally, 15 records from 13 RCTs met the eligibility criteria [13,14,15,16,17,18,19,21,22,23,24,25,26,28]. The process of evidence selection is shown in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…Most patients were female ( n = 1314; 73.6%). A total of seven trials used low dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) lower than 1000 mg per day [14,16,18,21,23,25,28], and the other four trials used high dose intervention by giving EPA and DHA more than 1000 mg per day [15,17,19,22]. There were only two trials that did not use EPA or DHA.…”

Section: Resultsmentioning

confidence: 99%

“…One of the two trials used α-Linolenic acid (ALA, 149 mg per day) and Linoleic acid (LA, 245 mg) per day [24], and the other one provided patients gamma-Linolenic acid (GLA, 30 mg) 30 and LA (57 mg) per day [13]. Among the 11 trials using EPA and DHA, four of them also provided patients GLA [16,21,23,28]. The GLA was usually given within 100 mg per day [13,16,23,28], and there was only one trial providing GLA 240 mg per day [21].…”

Section: Resultsmentioning

confidence: 99%

“…Among the 11 trials using EPA and DHA, four of them also provided patients GLA [16,21,23,28]. The GLA was usually given within 100 mg per day [13,16,23,28], and there was only one trial providing GLA 240 mg per day [21]. The details of PUFA in each trial can be found in Supplemental Material 2.…”

Section: Resultsmentioning

confidence: 99%

“…However, their results are heterogeneous. Some RCTs indicated that PUFAs significantly alleviated dry eye symptoms, and found improvement in both tear quality and quantity [13,14,15,16,17,18,19,20,21]. Nevertheless, other trials showed that PUFAs did not significantly improve TBUT and Schirmer test scores [22,23,24,25].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effects of Polyunsaturated Fatty Acids on Nonspecific Typical Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

2019

View full text Add to dashboard Cite

To investigate the effects of polyunsaturated fatty acids (PUFAs) in patients with dry eye disease (DED), a multifactorial inflammatory disorder, we searched Cochrane Library, EMBASE, PubMed, and Web of Science for randomized clinical trials (RCTs) investigating the effect of PUFAs in patients with DED before March 2019. Two reviewers independently abstracted data of tear breakup time (TBUT), Schirmer’s test, osmolarity, and ocular surface disease index (OSDI). We conducted pairwise meta-analysis using means and standard deviations (SDs) in a random-effects model for continuous outcomes. Thirteen eligible RCTs with 1782 patients with nonspecific typical DED were included. Patients who received PUFA treatment without other eye medications exhibited greater improvements in TBUT (MD = 1.80; p = 0.001), Schirmer test scores (MD = 0.50; p < 0.001), osmolarity (MD = −15.95; p < 0.001), and OSDI scores (MD = −10.19; p < 0.001) than those who received placebo treatment. However, the effects of PUFAs on TBUT (p < 0.001) and OSDI scores (p = 0.03) weakened with treatment duration. PUFAs are effective in treating nonspecific typical DED, particularly as a short-term treatment, with relatively few adverse events. Therefore, in real-world clinical practice, PUFA supplements are worth being suggested to patients with nonspecific typical DED who are not concurrently using other topical or systematic eye medications.

show abstract